(200 days)
Not Found
No
The device description and performance studies focus on the physical design and clinical effectiveness of a barrier contraceptive, with no mention of AI/ML or related concepts like image processing, training/test sets, or algorithmic performance metrics.
Yes.
The device is indicated for the prevention of pregnancy, which is a therapeutic purpose.
No
Explanation: The device is indicated for the prevention of pregnancy (contraception), not for diagnosing a condition or disease.
No
The device description clearly states it is a physical, contoured, flexible, single-sized, silicone elastomer cup with a rim encapsulating a nylon spring, which is a hardware component.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the "prevention of pregnancy in women who elect to use diaphragms as a method of contraception." This is a physical barrier method of contraception, not a diagnostic test performed on samples taken from the body.
- Device Description: The description details a physical device (a silicone cup with a spring) designed to cover the cervix. This is consistent with a physical barrier contraceptive.
- Lack of IVD Characteristics: The document does not mention any of the typical characteristics of an IVD, such as:
- Analyzing biological samples (blood, urine, tissue, etc.)
- Detecting or measuring substances in biological samples
- Providing information for diagnosis, monitoring, or screening of diseases or conditions
- Performance Studies: The performance studies focus on contraceptive effectiveness (pregnancy rates), which is relevant to a contraceptive device, not an IVD.
In summary, the Caya® contoured diaphragm is a medical device used for contraception, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The Caya® contoured diaphragm is indicated for the prevention of pregnancy in women who elect to use diaphragms as a method of contraception. It is recommended for use with a contraceptive gel.
Product codes (comma separated list FDA assigned to the subject device)
HDW
Device Description
The Caya® contoured diaphragm is a contoured, flexible, single-sized, silicone elastomer cup for covering the cervix that is circumscribed by a rim encapsulating a nylon spring. The Caya contoured diaphragm has an anatomically shaped spring that has been designed to fit women representing a range of traditional diaphragm sizes.
As with the predicate device, the Caya contoured diaphragm is inserted by squeezing the rim at the sides to fold the diaphragm into a narrow profile. The Caya® contoured diaphragm has grip dimples along the sides of the rim that provide a tactile cue as to where to squeeze the diaphragm during insertion. The single-size diaphragm was developed and tested as the SILCS diaphragm.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
cervix, vaginal wall
Indicated Patient Age Range
18–40 years old
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical Testing:
In a Phase I post coital study of barrier effectiveness, the SILCS diaphragm used with Nonoynol-9 (N-9) spermicide reduced the average number of progressively motile sperm per high powered field from a baseline of 12.5 to 0, confirming that the SILCS diaphragm would likely perform well in an effectiveness study.
The Phase II/II contraceptive effectiveness study-conducted at six sites in the United States-recruited 450 couples to participate in the study. Couples were randomized to two groups: 300 to SILCS diaphragm used with BufferGel (BG-an investigational lactic-acid based contraceptive gel) and 150 to SILCS diaphragm with N-9 spermicide gel. Healthy, sexually active female volunteers 18–40 years old, at risk for pregnancy, and desiring contraception but at low risk for HIV/STIs, were considered for enrollment. Eligible volunteers were not pregnant, had normal menstrual cycles, were not actively desiring pregnancy and were willing to accept an unknown risk of pregnancy and engage in at least 4 acts of vaginal intercourse per cycle. Participants were followed for at least 190 days and 6 menstrual cycles, and were seen at enrollment and after menstrual cycles 1. 3. and 6. Study outcomes included pregnancy probability. safety, acceptability, diaphragm fit, and ease of use. Results on effectiveness and safety were compared to an historical control group who used the ORTHO® ALL-FLEX® Diaphragm with these gels.
The historical control for the SILCS diaphragm pivotal study was a multi-center contraceptive study conducted by the National Institute for Child Health and Human Development (NICHD). That study demonstrated that BG used with an ORTHO® ALL-FLEX® Diaphragm worked about as well as N-9 with that diaphragm (6-month typical-use cumulative probability of pregnancy rates of 10.1 per 100 women (95% CI 7.1-13.1) and 12.3 (95% CI 7.7-16.9), respectively. The SILCS pivotal study was based on that previous study which was then used in the SILCS historical control analysis to compare the single-size SILCS diaphragm with the ORTHO® ALL-FLEX® Diaphragm on contraceptive effectiveness and safety.
In the SILCS pivotal study, 35 study pregnancies were reported which yielded 6-month Kaplan-Meier cumulative typical-use pregnancy probabilities per 100 women (with 95% confidence intervals) of 10.4 (6.9, 14.0), 9.6 (5.5, 13.6) and 12.5 (5.4, 19.5) for all SILCS with BG and SILCS with N-9, respectively. The rate for all SILCS users was non-inferior to the rate for all users of the ORTHO® ALL-FLEX® Diaphragm, using data from the historical control groups. The observed 6-month cumulative typical-use pregnancy probability was 10.4 per 100 women (95% CI: 6.9, 14.0). The observed 6-cycle cumulative perfect-use probability was 7.9 per 100 women (95% CI: 1.7. 14.0). Extrapolated to 12 months these estimates are for typical use: 17.8 per 100 women (95% CI: 12, 23.6) and for perfect use: 14.0 per 100 women (95% CI: 3.0, 23.6).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
6-month Typical use pregnancy probability: 10.4 (95% CI: 6.9, 14.0)
6-month Perfect use pregnancy probability: 7.9 (95% CI: 1.7, 14.0)
12-month Typical use pregnancy probability: 17.8 (95% CI: 12.0, 23.6)
12-month Perfect use pregnancy probability: 14.0 (95% CI: 3.0, 23.6)
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 884.5350 Contraceptive diaphragm and accessories.
(a)
Identification. A contraceptive diaphragm is a closely fitting membrane placed between the posterior aspect of the pubic bone and the posterior vaginal fornix. The device covers the cervix completely and is used with a spermicide to prevent pregnancy. This generic type of device may include an introducer.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol featuring three stylized human profiles facing to the right, stacked on top of each other.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
August 26, 2014
Kessel medintin GmbH Martin Kessel CEO Kelsterbacher Str. 28. 64546 Moerfelden-Walldorf, Frankfurt Germany
Re: K140305
Trade/Device Name: Caya® contoured diaphragm Regulation Number: 21 CFR§ 884.5350 Regulation Name: Contraceptive diaphragm and accessories Regulatory Class: II Product Code: HDW Dated: July 24, 2014 Received: July 28, 2014
Dear Martin Kessel,
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.
1
You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Herbert P. Lerner -S
for Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
4. Indications for Use Statement
510(k) Number (if known):
Device Name: Caya® contoured diaphragm
Indications for Use:
The Caya® contoured diaphragm is indicated for the prevention of pregnancy in women who elect to use diaphragms as a method of contraception. It is recommended for use with a contraceptive gel.
Prescription Use XXX Over-The-Counter Use AND/OR (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
3
510(k) Summary-Revised
Submitter Name
Kessel medintim GmbH
Submitter Address
Kelsterbacher Str. 28, 64546, Moerfelden-Walldorf, Frankfurt, Germany
Establishment Registration Number
Kessel medintim GmbH will register its establishment and list the Caya " contoured diaphragm prior to initial importation of any devices intended for commercial distribution within the United States.
Phone Number +49 6105 203 728
Fax Number +49 6105 455 901
Contact Person Martin Kessel
Date Prepared February 5, 2014 (revised July 23, 2014)
Device Trade Name Caya® contoured diaphragm
Common Name Diaphragm
Classification Name, Number, and Product Code
Classification Name: Contraceptive diaphragm and accessories (Class II)
Classification Number: 21 CFR §884.5350
Product Code: HDW
Predicate Devices ORTHO® ALL-FLEX® Diaphragm (silicone), Johnson & Johnson Produtos Profissionais Ltda. – A division of Johnson & Johnson, 510(k) number K080040.
Device Description and Statement of Intended Use
Description: The Caya® contoured diaphragm is a contoured, flexible, single-sized, silicone elastomer cup for covering the cervix that is circumscribed by a rim encapsulating a nylon spring. The Caya contoured diaphragm has an anatomically shaped spring that has been designed to fit women representing a range of traditional diaphragm sizes.
1 Caya is a registered trademark of Kessel medintim GmbH of Frankfurt, Germany.
2 The Caya contoured diaphragm was known as the SILCS diaphragm throughout design, development, and evaluation.
4
As with the predicate device, the Caya contoured diaphragm is inserted by squeezing the rim at the sides to fold the diaphragm into a narrow profile. The Caya® contoured diaphragm has grip dimples along the sides of the rim that provide a tactile cue as to where to squeeze the diaphragm during insertion. The single-size diaphragm was developed and tested as the SILCS diaphragm.
Statement of Intended Use: The Caya® contoured diaphragm is indicated for the prevention of pregnancy in women who elect to use diaphragms as a method of contraception. It is recommended for use with a contraceptive gel.
Summary of Technological Characteristics
When inserted into the vagina, the Caya® contoured diaphragm functions as a mechanical barrier that prevents sperm from entering the cervical canal. The spring within the perimeter of the device causes the device to create a seal against the vaginal wall, covering the cervix and preventing sperm from entering the cervical canal. The silicone cup also serves as a repository for contraceptive gel. See Table 5.1 (below) for a comparison of the Caya" contoured diaphragm to its predicate device, the ORTHO® ALL-FLEX® Diaphragm.
Performance Data
The subject device has passed biocompatibility testing in accordance with ISO 10993, performance testing in accordance with ISO 8009, and cleaning validation. Specifically the device has been subjected to and passed the following biocompatibility and performance tests:
Biocompatability testing
- . Cytotoxicity Growth Inhibition Test
- . Vaginal Irritation Study
- Delayed Type Hypersensitivity
- Genotoxicity, bacterial reverse mutation study ●
- Inductively Coupled Plasma Investigations ●
- Gas Chromato-graphic and FTIR Fingerprint Investigations ●
- ISO intracutaneous study ●
- Mouse peripheral blood microcutaneous study ●
- Genotoxicity, mouse lymphoma ●
- 12-week muscle implant ●
- Subchronic Systemic Toxicity
Performance testing
- Visual inspection
- Weight ●
- Kneel-down bending ●
- Membrane tensile strength and elongation ●
- Shore A hardness
- Membrane thickness
- Chemical resistance ●
- Compression Test ●
- Twist Test ●
5
Clinical Testing
In a Phase I post coital study of barrier effectiveness, the SILCS diaphragm3 used with Nonoynol-9 (N-9) spermicide reduced the average number of progressively motile sperm per high powered field from a baseline of 12.5 to 0, confirming that the SILCS diaphragm would likely perform well in an effectiveness study.
The Phase II/II contraceptive effectiveness study-conducted at six sites in the United States-recruited 450 couples to participate in the study. Couples were randomized to two groups: 300 to SILCS diaphragm used with BufferGel (BG-an investigational lactic-acid based contraceptive gel) and 150 to SILCS diaphragm with N-9 spermicide gel. Healthy, sexually active female volunteers 18–40 years old, at risk for pregnancy, and desiring contraception but at low risk for HIV/STIs, were considered for enrollment. Eligible volunteers were not pregnant, had normal menstrual cycles, were not actively desiring pregnancy and were willing to accept an unknown risk of pregnancy and engage in at least 4 acts of vaginal intercourse per cycle. Participants were followed for at least 190 days and 6 menstrual cycles, and were seen at enrollment and after menstrual cycles 1. 3. and 6. Study outcomes included pregnancy probability. safety, acceptability, diaphragm fit, and ease of use. Results on effectiveness and safety were compared to an historical control group who used the ORTHO® ALL-FLEX® Diaphragm with these gels.
The historical control for the SILCS diaphragm pivotal study was a multi-center contraceptive study conducted by the National Institute for Child Health and Human Development (NICHD). That study demonstrated that BG used with an ORTHO® ALL-FLEX® Diaphragm worked about as well as N-9 with that diaphragm (6-month typical-use cumulative probability of pregnancy rates of 10.1 per 100 women (95% CI 7.1-13.1) and 12.3 (95% CI 7.7-16.9), respectively. * The SILCS pivotal study was based on that previous study which was then used in the SILCS historical control analysis to compare the single-size SILCS diaphragm with the ORTHO® ALL-FLEX® Diaphragm on contraceptive effectiveness and safety.
In the SILCS pivotal study, 35 study pregnancies were reported which yielded 6-month Kaplan-Meier cumulative typical-use pregnancy probabilities per 100 women (with 95% confidence intervals) of 10.4 (6.9, 14.0), 9.6 (5.5, 13.6) and 12.5 (5.4, 19.5) for all SILCS with BG and SILCS with N-9, respectively. The rate for all SILCS users was non-inferior to the rate for all users of the ORTHO® ALL-FLEX® Diaphragm, using data from the historical control groups. The observed 6-month cumulative typical-use pregnancy probability was 10.4 per 100 women (95% CI: 6.9, 14.0). The observed 6-cycle cumulative perfect-use probability was 7.9 per 100 women (95% CI: 1.7. 14.0). Extrapolated to 12 months these estimates are for typical use: 17.8 per 100 women (95% CI: 12, 23.6) and for perfect use: 14.0 per 100 women (95% CI: 3.0, 23.6) (See Table 1 (below)).
3 The Caya® contoured diaphragm was known as the SILCS diaphragm throughout design, development, and evaluation.
4 Barnhart KT, Rosenberg MJ, MacKay HT, et al. Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial. Obstet Gynecol. 2007;110(3):577-586.
6
| | Estimated number of
pregnancies per 100 women
during time period | 95% confidence interval |
|--------------|------------------------------------------------------------------------|-------------------------|
| 6 months | | |
| Typical use | 10.4 | 6.9, 14.0 |
| Perfect use* | 7.9 | 1.7, 14.0 |
| | | |
| 12 months | | |
| Typical use | 17.8 | 12.0, 23.6 |
| Perfect use | 14.0 | 3.0, 23.6 |
Table. 5.1. Typical and Perfect Use Pregnancy Probabilities at 6- and 12-months
*6-cycle
Conclusion
Differences in technological characteristics between the Caya® contoured diaphragm and the predicate device raise no new safety concerns, and the devices have intended use. Results from the pivotal study show that the single-sized Caya diaphragm used with a contraceptive gel provided similar use effectiveness as results from a previously implemented study that evaluated the predicate device (ORTHO® ALL-FLEX® Diaphragm) used with the same contraceptive gels. The single-sized Caya diaphragm has a similar clinical safety profile as the predicate device. The above information demonstrates that the single-sized Caya diaphragm is substantially equivalent to the predicate device.
7
| Attribute | Subject device | Predicate device |
|---|---|---|
| Device information | ||
| Trade/Device name | Caya® contoured diaphragm | ORTHO® ALL-FLEX® |
| Diaphragm | ||
| 510(k) number | K140305 | K080040 |
| Manufacturer | Kessel medintim GmbH | Johnson & Johnson Produtos |
| Profissionais Ltda. – A division | ||
| of Johnson & Johnson | ||
| Classification/Product code | 21 CFR §884.5350 / HDW | 21 CFR §884.5350 / HDW |
| Similarities | ||
| Indication for use | The Caya® contoured diaphragm is | |
| indicated for the prevention of | ||
| pregnancy in women who elect to | ||
| use diaphragms as a method of | ||
| contraception. It is recommended | ||
| for use with a contraceptive gel. | The ORTHO® ALL-FLEX® | |
| Diaphragm, in conjunction with | ||
| an appropriate spermicide, is | ||
| indicated for the prevention of | ||
| pregnancy in women who elect | ||
| to use diaphragms as a method | ||
| of contraception. | ||
| Mode of action | Mechanical contraceptive barrier | Same |
| Reusable | Yes | Same |
| Material (barrier) | Medical-grade silicone | Same |
| Standard of conformity | ISO 8009:2004(E) | Same |
| Differences | ||
| Rim shape | Anatomically contoured (arcing | |
| spring) in one size (60 to 85 mm) | Circular (arcing spring) in four | |
| sizes (65, 70, 75, and 80 mm) | ||
| Spring stiffness (relative) | Soft | Stiff |
| Grip dimples | Present | Not present |
| Finger removal dome | Present | Not present |
| Material: spring | Nylon | Metal |
| Material: color (of silicone) | Violet | Buff |
Table 5.2. Summary comparison of technological characteristics between the single-sized Caya contoured diaphragm and its predicate.